Chemical Information
Antiviral agent ID	DrugRepV_4353
Antiviral agent name	N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide
IUPAC Name	N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide
SMILES (canonical)	C1=CC(=C(C=C1NS(=O)(=O)C2=CC3=C(C=C2)NC(=O)O3)Cl)Cl
Molecular Formula	C13H8Cl2N2O4S
Molecular Weight (g/mol)	359.2
InChl	InChI=1S/C13H8Cl2N2O4S/c14-9-3-1-7(5-10(9)15)17-22(19,20)8-2-4-11-12(6-8)21-13(18)16-11/h1-6,17H,(H,16,18)
Structural Information
Clinical Information
Biological Information
Secondary Indication	Ebola virus (EBOV) NA GP, amino acids 196 to 205
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	293FT
Secondary Indication (Viral titer)	1 μM
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	40 μM
Secondary Indication (Cell based assay)	CatL-Peptide cleavage
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Percentage inhibition [ 33.4 % ]
Reference	Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS..Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay..J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5. PubMed Central PMCID: P PMID:24501399
Comment	A novel broad-spectrum small molecule that could block cathepsin L-mediated cleavage was identified and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-CoV or Ebola, Hendra, or Nipah virus. The small molecule can be further optimized and developed into a potent broad-spectrum antiviral drug.